FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2064984806> ?p ?o ?g. }

• W2064984806 endingPage "43245" @default.
• W2064984806 startingPage "43234" @default.
• W2064984806 abstract "Activation of lipid metabolism is an early event in carcinogenesis and a central hallmark of many tumors. Fatty acid synthase (FASN) is a key lipogenic enzyme catalyzing the terminal steps in the de novo biogenesis of fatty acids. In cancer cells, FASN may act as a metabolic oncogene, given that it confers growth and survival advantages to these cells, whereas its inhibition effectively and selectively kills tumor cells. Hormones such as estrogens and growth factors contribute to the transcriptional regulation of FASN expression also through the activation of downstream signaling and a cross-talk among diverse transduction pathways. In this study, we demonstrate for the first time that 17β-estradiol (E2) and the selective GPER ligand G-1 regulate FASN expression and activity through the GPER-mediated signaling, which involved the EGF receptor/ERK/c-Fos/AP1 transduction pathway, as ascertained by using specific pharmacological inhibitors, performing gene-silencing experiments and ChIP assays in breast SkBr3, colorectal LoVo, hepatocarcinoma HepG2 cancer cells, and breast cancer-associated fibroblasts. In addition, the proliferative effects induced by E2 and G-1 in these cells involved FASN as the inhibitor of its activity, named cerulenin, abolished the growth response to both ligands. Our data suggest that GPER may be included among the transduction mediators involved by estrogens in regulating FASN expression and activity in cancer cells and cancer-associated fibroblasts that strongly contribute to cancer progression. Activation of lipid metabolism is an early event in carcinogenesis and a central hallmark of many tumors. Fatty acid synthase (FASN) is a key lipogenic enzyme catalyzing the terminal steps in the de novo biogenesis of fatty acids. In cancer cells, FASN may act as a metabolic oncogene, given that it confers growth and survival advantages to these cells, whereas its inhibition effectively and selectively kills tumor cells. Hormones such as estrogens and growth factors contribute to the transcriptional regulation of FASN expression also through the activation of downstream signaling and a cross-talk among diverse transduction pathways. In this study, we demonstrate for the first time that 17β-estradiol (E2) and the selective GPER ligand G-1 regulate FASN expression and activity through the GPER-mediated signaling, which involved the EGF receptor/ERK/c-Fos/AP1 transduction pathway, as ascertained by using specific pharmacological inhibitors, performing gene-silencing experiments and ChIP assays in breast SkBr3, colorectal LoVo, hepatocarcinoma HepG2 cancer cells, and breast cancer-associated fibroblasts. In addition, the proliferative effects induced by E2 and G-1 in these cells involved FASN as the inhibitor of its activity, named cerulenin, abolished the growth response to both ligands. Our data suggest that GPER may be included among the transduction mediators involved by estrogens in regulating FASN expression and activity in cancer cells and cancer-associated fibroblasts that strongly contribute to cancer progression." @default.
• W2064984806 created "2016-06-24" @default.
• W2064984806 creator A5006447905 @default.
• W2064984806 creator A5011806303 @default.
• W2064984806 creator A5012914217 @default.
• W2064984806 creator A5014208008 @default.
• W2064984806 creator A5014579151 @default.
• W2064984806 creator A5021882845 @default.
• W2064984806 creator A5030512533 @default.
• W2064984806 creator A5039725997 @default.
• W2064984806 creator A5049061975 @default.
• W2064984806 creator A5065149587 @default.
• W2064984806 creator A5074738070 @default.
• W2064984806 date "2012-12-01" @default.
• W2064984806 modified "2023-10-18" @default.
• W2064984806 title "G Protein-coupled Estrogen Receptor Mediates the Up-regulation of Fatty Acid Synthase Induced by 17β-Estradiol in Cancer Cells and Cancer-associated Fibroblasts" @default.
• W2064984806 cites W1719051208 @default.
• W2064984806 cites W1964506243 @default.
• W2064984806 cites W1967482096 @default.
• W2064984806 cites W1969933703 @default.
• W2064984806 cites W1974511120 @default.
• W2064984806 cites W1975180674 @default.
• W2064984806 cites W1991405930 @default.
• W2064984806 cites W1995318696 @default.
• W2064984806 cites W1998740208 @default.
• W2064984806 cites W1999337092 @default.
• W2064984806 cites W2000566591 @default.
• W2064984806 cites W2010578103 @default.
• W2064984806 cites W2012124753 @default.
• W2064984806 cites W2012699684 @default.
• W2064984806 cites W2017826746 @default.
• W2064984806 cites W2020133693 @default.
• W2064984806 cites W2026825834 @default.
• W2064984806 cites W2028893107 @default.
• W2064984806 cites W2031390537 @default.
• W2064984806 cites W2037790468 @default.
• W2064984806 cites W2038208040 @default.
• W2064984806 cites W2057975870 @default.
• W2064984806 cites W2062809449 @default.
• W2064984806 cites W2066441904 @default.
• W2064984806 cites W2070397307 @default.
• W2064984806 cites W2075261412 @default.
• W2064984806 cites W2077328356 @default.
• W2064984806 cites W2077399441 @default.
• W2064984806 cites W2078275530 @default.
• W2064984806 cites W2090121445 @default.
• W2064984806 cites W2092184448 @default.
• W2064984806 cites W2093265805 @default.
• W2064984806 cites W2095587552 @default.
• W2064984806 cites W2100521322 @default.
• W2064984806 cites W2101037339 @default.
• W2064984806 cites W2103847243 @default.
• W2064984806 cites W2104424545 @default.
• W2064984806 cites W2114197848 @default.
• W2064984806 cites W2116043556 @default.
• W2064984806 cites W2122015809 @default.
• W2064984806 cites W2123476163 @default.
• W2064984806 cites W2125000296 @default.
• W2064984806 cites W2126437849 @default.
• W2064984806 cites W2129564497 @default.
• W2064984806 cites W2135715116 @default.
• W2064984806 cites W2139126860 @default.
• W2064984806 cites W2143176261 @default.
• W2064984806 cites W2143424493 @default.
• W2064984806 cites W2146012616 @default.
• W2064984806 cites W2149713530 @default.
• W2064984806 cites W2153178365 @default.
• W2064984806 cites W2153777175 @default.
• W2064984806 cites W2161185871 @default.
• W2064984806 cites W2164804511 @default.
• W2064984806 cites W2171874512 @default.
• W2064984806 cites W2333137319 @default.
• W2064984806 doi "https://doi.org/10.1074/jbc.m112.417303" @default.
• W2064984806 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3527911" @default.
• W2064984806 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23135268" @default.
• W2064984806 hasPublicationYear "2012" @default.
• W2064984806 type Work @default.
• W2064984806 sameAs 2064984806 @default.
• W2064984806 citedByCount "86" @default.
• W2064984806 countsByYear W20649848062013 @default.
• W2064984806 countsByYear W20649848062014 @default.
• W2064984806 countsByYear W20649848062015 @default.
• W2064984806 countsByYear W20649848062016 @default.
• W2064984806 countsByYear W20649848062017 @default.
• W2064984806 countsByYear W20649848062018 @default.
• W2064984806 countsByYear W20649848062019 @default.
• W2064984806 countsByYear W20649848062020 @default.
• W2064984806 countsByYear W20649848062021 @default.
• W2064984806 countsByYear W20649848062022 @default.
• W2064984806 countsByYear W20649848062023 @default.
• W2064984806 crossrefType "journal-article" @default.
• W2064984806 hasAuthorship W2064984806A5006447905 @default.
• W2064984806 hasAuthorship W2064984806A5011806303 @default.
• W2064984806 hasAuthorship W2064984806A5012914217 @default.
• W2064984806 hasAuthorship W2064984806A5014208008 @default.
• W2064984806 hasAuthorship W2064984806A5014579151 @default.
• W2064984806 hasAuthorship W2064984806A5021882845 @default.
• W2064984806 hasAuthorship W2064984806A5030512533 @default.

• next